Calithera Biosciences Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Calithera Biosciences Inc had its IPO on 2014-10-02 under the ticker symbol CALA.
The company operates in the Healthcare sector and Biotechnology industry. Calithera Biosciences Inc has a staff strength of 63 employees.
Shares of Calithera Biosciences Inc opened at $0.05 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $0.04 - $0.05, and closed at $0.04.
This is a -2% slip from the previous day's closing price.
A total volume of 2,848 shares were traded at the close of the day’s session.
In the last one week, shares of Calithera Biosciences Inc have slipped by -26.5%.
Calithera Biosciences Inc's Key Ratios
Calithera Biosciences Inc has a market cap of $199476, indicating a price to book ratio of 1.8639 and a price to sales ratio of 1.7108.
In the last 12-months Calithera Biosciences Inc’s revenue was $0 with a gross profit of $-42705000 and an EBITDA of $-102482000. The EBITDA ratio measures Calithera Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Calithera Biosciences Inc’s operating margin was 0% while its return on assets stood at -101.08% with a return of equity of -202.22%.
In Q3, Calithera Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Calithera Biosciences Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-18.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.29. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Calithera Biosciences Inc’s profitability.
Calithera Biosciences Inc stock is trading at a EV to sales ratio of 0.0141 and a EV to EBITDA ratio of 0.0409. Its price to sales ratio in the trailing 12-months stood at 1.7108.
Calithera Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $37.08 million
- Total Liabilities
- $9.23 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Calithera Biosciences Inc ended 2023 with $37.08 million in total assets and $0 in total liabilities. Its intangible assets were valued at $37.08 million while shareholder equity stood at $26.39 million.
Calithera Biosciences Inc ended 2023 with $0 in deferred long-term liabilities, $9.23 million in other current liabilities, in common stock, $-505680000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $34.07 million and cash and short-term investments were $34.07 million. The company’s total short-term debt was $1,490,000 while long-term debt stood at $0.
Calithera Biosciences Inc’s total current assets stands at $34.70 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.01 million and inventory worth $0.
In 2023, Calithera Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $110000.
Comparatively, Calithera Biosciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Calithera Biosciences Inc stock is currently trading at $0.04 per share. It touched a 52-week high of $13.376 and a 52-week low of $13.376. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $0.18 and 200-day moving average was $2.22 The short ratio stood at 0.78 indicating a short percent outstanding of 0%.
Around 124.6% of the company’s stock are held by insiders while 3022.2% are held by institutions.
Frequently Asked Questions About Calithera Biosciences Inc
Similar Industry Stocks (Biotechnology)
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer’s PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.